BiVictriX appoints Richard Bethell as Senior Scientific Consultant
Updated: Jul 2, 2019
Alderley Park, United Kingdom — BiVictriX announces today that it has appointed Richard Bethell as as a Senior Scientific Consultant, effective from June XX, 2019.
In his role as Senior Scientific Consultant, Richard will lead BiVictriX’s R&D efforts to discover and develop new classes of cancer drugs based on BiVictriX’s expertise in bispecific therapeutics.
Richard brings nearly 30 years’ experience in drug discovery and development in the biopharmaceutical industry. Most recently Richard was Chief Scientific Officer at Medivir AB, where he oversaw the renewal of the company’s R&D strategy, transforming the company from a broad-based early discovery organization into a clinical stage oncology company. Under his scientific leadership, Medivir built a portfolio of development stage cancer projects, including MIV-818, a novel agent for the treatment of liver cancers, and MIV-828, which has been designed for the treatment of acute myeloid leukemia. Before joining Medivir, Richard held senior positions in in the R&D organizations of Boehringer Ingelheim, Shire, Pfizer and GSK. He holds a D. Phil. in Chemistry from the University of Oxford.
“I am delighted to welcome Richard to BiVictriX. He brings an outstanding combination of accomplishment in drug discovery and development as well as expertise in disease areas that are highly relevant to BiVictriX’s R&D strategy. I look forward to his contributions in supporting the expansion of BiVictriX’s R&D portfolio.” says Tiffany Thorn, CEO at BiVictriX.
“BiVictrix’s technology, enabling the discovery and development of a new generation of antibody drug conjugates and targeted immunotherapies, offers enormous potential to bring transformative drugs to cancer patients. I am very excited to join BiVictriX at such an exciting time in the company’s development.” says Richard Bethell
For further information, please contact Tiffany Thorn, CEO, BiVictriX Ltd., phone: +44 7908 719566
BiVictriX Ltd. Is a privately-held biopharmaceutical company based in the UK that employs its proprietary Bi-Cygni® technology platform to discover and develop the next generations of targeted immunotherapeutics for the treatment of cancer. The Bi-Cygni® platform enables the identification of pairs of surface antigens for obligate bispecific therapeutics, enhancing the specificity for the tumour, andreducing the treatment-related toxicity that currently hinders the development of otherwise promising cancer therapeutics. BiVictriX links Bi-Cygni® to expertise in the design, discovery and development of antibody drug conjugates (ADCs), and its current lead project, BVX001, is a bispecific ADC for the treatment of Acute Myeloid Leukemia (AML).